請輸入關鍵字:

熱門搜尋:

Arthur D. Little Report Explores Impact of “Ultra-targeted” Healthcare

日期:2019年5月7日 下午4:15

All segments of healthcare will need to adapt to unprecedented change driven by technological advancements in areas such as molecular biology, AI and digitalization

BOSTON--(BUSINESS WIRE)-- As pivotal changes in healthcare and drug development gain traction, new analysis from Arthur D. Little (ADL) highlights that all sectors of the industry must evolve their business and operating models in the coming decade.

From genomic treatments to Artificial Intelligence in diagnostics to leaps in curative medicine, the healthcare ecosystem is facing unprecedented change. ADL’s forward-looking assessment is captured in a new Report, “Future Health: How the industry will move from ‘one size fits all’ to ultra-targeted care.”

Several critical shifts are pushing major players across the world to adapt:

  • Targeted treatments are changing the way drugs are brought to market, with greater emphasis on patients’ biological make-ups. Already, 22% of drugs currently in development specify a biomarker as criteria for inclusion, according to ADL research.
  • ADL projects the global consumer genetic testing market will reach $50B by 2026, leading to an abundance of genomic data that will be available to guide prevention, diagnosis, and treatment.
  • Certain chronic diseases will become more curable or treatable, and patients with access to more data will have greater opportunity to prevent or manage their conditions.
  • Long-term care will continue to shift away from hospitals, which will in turn move their model from surgeries and long-term chronic care to a physician-led approach to curative therapies, and may lead them to consider onsite device and drug manufacturing.

Craig Wylie, Managing Partner at ADL in the United States, notes: “Incredible advances in genomics and diagnostics are leading to a future that will impact the entire breadth of the healthcare industry. Companies are in the early stages of evolving their approach to clinical trials, commercial models, and care provision.”

“The pace of change and the associated costs will be staggering,” continued Wylie. “The most successful organizations across all segments of the healthcare ecosystem will be those that adapt their business models, rethink their operations, and place an emphasis on collaboration and partnerships.”

To download the Report, please visit: www.adl.com/FutureHealth

Contacts

Cate Bonthuys
Catalyst Comms
cate@catalystcomms.co.uk
Tel: +44 7746546773

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載財華財經APP,把握投資先機
https://www.finet.com.cn/app

更多精彩内容,請點擊:
財華網(https://www.finet.hk/)
財華智庫網(https://www.finet.com.cn)
現代電視FINTV(https://www.fintv.hk)

相關文章

5月7日
Arthur D. Little報告探討了「超目標」醫療保健的影響
5月7日
Favro被Gartner評為最酷供應商
5月7日
印尼第三任總統哈比比在巴淡島的10億美元超級地塊吸引全球投資者的目光,目前已推出豪華的Erleseen Tower專案
5月7日
Algorand基金會公佈研究負責人
5月7日
新益美集團全球排名大幅躍升
5月7日
Allied World宣佈推出伊斯蘭再保險窗口
5月7日
B-Yond任命Vince Molinaro為執行顧問
5月7日
Aryaka籌資5,000萬美元以加速全球代管SD-WAN擴張
5月7日
VivaTech 2019: Thales Receives Global Innovator Award and Invites Visitors to Be Astronauts for a Day
5月7日
CURRENCY.COM推出全新手機應用程式並擴大香港證券交易市場

視頻

快訊

20:03
海南封關落地!板塊投資機遇幾何?
19:46
機器人板塊集體走強,人形機器人從「炫技」邁向「上崗」
17:34
國家網信辦會同中國證監會深入整治涉資本市場網上虛假不實信息
17:28
碩奧國際(02336.HK):馮櫓銘獲任董事會主席
17:19
復宏漢霖(02696.HK)HLX18治療多種實體瘤的1期臨床試驗申請獲美FDA批准
17:11
國家外匯局:11月銀行結匯2095億美元 售匯1938億美元
17:04
中國白銀集團(00815.HK)認購協議已部分完成
16:50
美高梅中國(02282.HK):馮小峰獲任首席執行官
16:39
超大現代(00682.HK)完成配售3295萬股 淨籌約719萬港元
16:32
香港10月批出六份建築圖則